LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lifevantage Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
Share price
−$2.83 (−32.12%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Lifevantage Corp saw revenue fall 20.1% to $182.59M over the twelve months to Jun 30, 2026. Operating income fell 50.0% to $6.10M, moving the operating margin from 5.3% to 3.3%. Free cash flow was $6.67M, down 36.5% from a year earlier.
Revenue
$182.59M
-20.1% vs. a year earlier
Operating income
$6.10M
-50.0% vs. a year earlier
Free cash flow
$6.67M
-36.5% vs. a year earlier
EPS, diluted
$0.40
-46.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $74.97M
- P/E ratio
- 15.0
- Price to sales
- 0.41
- Price to book
- 2.23
- Dividend yield
- 3.09%
- Free cash flow yield
- 8.90%
Fundamentals
- Revenue
- $182.59M
- Net income
- $5.07M
- EPS, diluted
- $0.40
- Free cash flow
- $6.67M
- Book value per share
- $2.68
- Diluted shares
- 13M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$182.59M-20.1% YoY
Gross profit
$141.61M-22.9% YoY
Operating income
$6.10M-50.0% YoY
Net income
$5.07M-48.3% YoY
EPS, diluted
$0.40-46.7% YoY
Free cash flow
$6.67M-36.5% YoY
Reported period